A 60-week real-world experience with guselkumab in patients with moderate-to-severe plaque psoriasis including patients with malignancy: A retrospective study from Ontario, Canada
Main Authors: | Manal Al-Rabai, Lujain Al-Ghanemi, Julia Steriopoulos, Ahmad Saleem, Mohannad Abu-Hilal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Journal of Dermatology and Dermatologic Surgery |
Online Access: | http://www.jddsjournal.org/article.asp?issn=2352-2410;year=2023;volume=27;issue=2;spage=90;epage=92;aulast=Al-Rabai |
Similar Items
-
Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01) -
Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
by: Richard G. Langley, MD, et al.
Published: (2024-06-01) -
Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01) -
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
by: Andrew Blauvelt, et al.
Published: (2022-05-01) -
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series
by: Marco Galluzzo, et al.
Published: (2024-02-01)